SCHEMBL4030097

SCHEMBL4030097

CSc1nc(N)nc(-c2ccc(Oc3ccccc3)cc2)n1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.74
HSP90AB1 P08238 1/20 0.74
HPGD P15428 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
ALDH1A1 P00352 2/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
ADORA2A P29274 4/20 0.52
ADORA1 P30542 4/20 0.52
IKBKB O14920 1/20 0.52
BRAF P15056 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
DHFR P00374 1/20 0.48
POLB P06746 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
ADORA2B P29275 1/20 0.47
TPH1 P17752 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4093530 0.86 HSP90AA1 (1.00) HSP90AA1HSP90AB1ADORA2AADORA1MEN1
SCHEMBL6983205 0.84 IKBKB (0.70) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1
SCHEMBL6316030 0.83 HSP90AA1 (0.66) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1
SCHEMBL6306895 0.78 HSP90AA1 (0.59) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1
SCHEMBL6309967 0.78 HSP90AA1 (0.72) HSP90AA1HSP90AB1HPGDSMN1; SMN2CYP1A2
SCHEMBL6310578 0.76 HSP90AA1 (0.70) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1
SCHEMBL6314171 0.74 NPC1 (0.72) HSP90AA1HSP90AB1CYP1A2CYP2C19ADORA2A
SCHEMBL6314388 0.74 HSP90AA1 (0.66) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1
SCHEMBL21887691 0.73 MAPK1 (0.58) HPGDALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL25604007 0.73 HSP90AA1 (0.75) HSP90AA1HSP90AB1HPGDSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US claimed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP claimed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO claimed
EP-1265866-B1 ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF EURO CELTIQUE SA (LU) 2010-07-21 EP disclosed
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors ASTEX THERAPEUTICS LTD. (GB) 2009-08-27 US disclosed
EP-2051962-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-04-29 EP disclosed
EP-2049497-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS Astex Therapeutics Limited (GB) 2009-04-22 EP disclosed
WO-2008017989-A1 (3-AMINO-1,2,3,4-TETRAHYDRO-9H-CARBAZOL-9-YL)-ACETIC ACID DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-02-14 WO disclosed
WO-2006123165-A2 PYRIMIDINE DERIVATIVES AS HSP90 INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215777-A1 Pyrimidine Derivatives As HSP90 Inhibitors HSP90AB1, HSP90AB2P, HSP90B1 HSP90AA1 4/4885HSP90AB1 1/4885HPGD 1647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.